Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis

Abstract

Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected. The expression of C7 was analyzed using reverse transcriptase quantitative polymerase chain reaction. As a result, the C7 expression displayed a gradual downward trend in normal, benign, borderline and malignant ovarian tissues, and the decreased expression of C7 was correlative to poor differentiation in patients with ovarian cancer. Interestingly, a similar change of expression of C7 was found in normal, adjacent and malignant tissues in patients with NSCLC, and low expression of C7 was associated with worse grade and advanced clinical stage. Both results from this cohort and the public database indicated that NSCLC patients with low expression of C7 had a worse outcome. Furthermore, multivariate cox regression analysis showed NSCLC patients with low C7 had a 3.09 or 5.65-fold higher risk for relapse or death than those with high C7 respectively, suggesting C7 was an independent prognostic predictor for prognoses of patients with NSCLC. Additionally, overexpression of C7 inhibited colony formation of NSCLC cells, which hints C7 might be a potential tumor suppressor.

A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome

“…Given the high number of cancer types exhibiting a coordinated expression decrease (or increase) of these core secretome genes, we reasoned that these genes would likely be responsible for important tumor-specific functions. Many of the genes exhibiting decreased expression are putative or established tumor suppressors (e.g., ANGPTL1, C2orf40, CHRDL1, OGN, C7, GREM2) ( Hu et al, 2018 ; Kuo et al, 2013 ; Li et al, 2015 ; Pei et al, 2017 ; Tsubamoto et al., 2016 ; Ying et al, 2016 ), are involved in the remodeling of the extracellular matrix (ECM) (e.g., DNASE1L3, CLEC3B, PI16, CCBE1) ( Barton et al, 2010 ; Hawes et al., 2015 ; Hazell et al, 2016 ; Obrist et al, 2004 ), and/or participate in cell-matrix adhesion functions (e.g., MFAP4, DPT, MAMDC2) ( Avilés-Vázquez et al, 2017 ; Pilecki et al, 2016 ; Yamatoji et al, 2012 ).…”

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

“…Elevated serum levels of C7 have been linked to a better prognosis in ovarian and non-small cell lung cancer (NSCLC). Additionally, overexpression of C7 was shown to inhibit the colony formation of NSCLC cells, which indicates that C7 might be a potential tumor suppressor [44].…”

Systems-level differential gene expression analysis reveals new genetic variants of oral cancer

“…It has been studied that ANAPC13 41 is a large-sized ubiquitin ligase that controls the cell cycle progression 42 and involved at early steps of malignancy in tumor cells 43 . Similarly, C7 (complement component-7), the terminal component for complement cascade and as a cytolytic effector for complement system, lyses transformed malignant cells [44][45][46][47][48][49][50][51] . The integration of chemical-gene interaction revealed different environmental chemical exposure to disease progression 52,53 .…”